Serina Therapeutics Inc（SER）の財務SERSerina Therapeutics Inc

Evaluating the bottom line, Serina Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -305.13%, provide a clear picture of how effectively SER converts its operational activities into shareholder value.

In the context of the broader market, SER competes directly with industry leaders such as FJET and CIGL. With a market capitalization of $34.80M, it holds a significant position in the sector. When comparing efficiency, SER's gross margin of N/A stands against FJET's N/A and CIGL's -159.68%. Such benchmarking helps identify whether Serina Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Serina Therapeutics has faced significant financial losses, with a net income of -$6.9 million in Q1 2026 and -$8.9 million in Q2 2026. The company has not generated substantial revenue, reporting only $130,000 in Q2 2025. Despite this, the gross margin is high at 100% for some quarters, indicating potential for profitability if revenue can be increased.